uniQure Q1 net loss per share $0.82; AMT-130 granted FDA Breakthrough Therapy designation

uniQure N.V.

2025-Q1 EPS reported -$0.82 revenue$1,567,000

Net loss $43.6M ($0.82 per share) vs $65.6M ($1.36) in Q1 2024; revenue down to $1.6M from $8.5M.
Cash and investments $409M as of Mar 31, 2025; expects funding into H2 2027.
AMT-130 for Huntington's disease granted FDA Breakthrough Therapy designation in Apr 2025.
BLA submission guidance for AMT-130 expected in Q2 2025 after official meeting minutes.
Initial AMT-260 epilepsy data to be presented May 29, 2025; AMT-191 Fabry data in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.